

Turn complexity into **confidence**

Across all cohorts, including in hostile aortic necks, the GORE® EXCLUDER® Conformable AAA Endoprosthesis delivers proven clinical outcomes.

Pivotal trial study design^{1,2}

■ Short neck sub-study:

Subjects with AAA aortic neck angulation $\leq 60^\circ$ and infrarenal aortic neck length ≥ 10 mm.

■ High neck angulation sub-study:

Subjects with AAA aortic neck angulation $> 60^\circ$ and $\leq 90^\circ$ and infrarenal aortic neck length ≥ 10 mm.

Subjects by neck characteristic		Neck angle	
		$\leq 60^\circ$	$> 60^\circ$ to $\leq 90^\circ$
Neck length	≥ 15 mm	57	74
	≥ 10 to < 15 mm	23	21

Outcomes through 36 months

Aortic neck characteristics	≥ 15 mm $\leq 60^\circ$	$\geq 10 - < 15$ mm $\leq 60^\circ$	≥ 15 mm $> 60^\circ - \leq 90^\circ$	$\geq 10 - < 15$ mm $> 60^\circ - \leq 90^\circ$	All necks
Subjects total ^a	57	23	74	21	175
Procedural technical success ^b	100%	100%	97.3%	100%	98.9%
Device compression (ie, kink)	0%	0%	1.4%	0%	0.6%
Migration	0%	0%	0%	0%	0%
Type I endoleak ^c	0%	0%	5.4%	0%	2.3%
Type III endoleak	0%	0%	0%	0%	0%
Reintervention	10.5%	4.3%	17.6%	4.8%	12%
Conversion to open repair	0%	0%	4.1%	0%	1.7%
AAA rupture	0%	0%	1.4%	0%	0.6%
Aneurysm-related mortality	0%	0%	0%	0%	0%
Device-related SAEs	0%	0%	4.10%	0%	1.70%
AAA sac diameter change ^d					
≥ 5 mm decrease	58.1%	58.3%	42.5%	60.0%	52.4%
No change	32.6%	25.0%	37.5%	20.0%	32.4%
≥ 5 mm increase	9.3%	16.7%	20.0%	20.0%	15.2%

^a Clinical and imaging events reported cumulative through 36 months (denominator is any evaluable visit through 36 months).

^b Technical success was not achieved in 2 subjects with Type I endoleaks on completion angiography; these resolved prior to the first postoperative scan.


^c All Type I endoleaks occurred prior to 12-month window and resolved without treatment.

^d AAA sac diameter assessed at 36-month visit.

Confidence built on control, innovation anchored in trust

Treating complex aortic anatomy demands confidence in your device. The GORE® EXCLUDER® Conformable AAA Endoprosthesis uniquely delivers control, adaptability, and durable performance — so you can stay focused on patient outcomes, not device limitations.

- Enhanced conformability
 - Individual stent rows allow for flexibility.
 - Nesting stent rows to maximize wall apposition and seal.
- Unique repositioning
 - Initial trunk deployment at ~ 70% diameter.
 - Reconstrainable proximal anchors for refined positioning.
- The only device with angulation control
 - Optional angulation control at 2 stages.
 - Helps optimize seal in highly angulated necks.



References

1. Assessment of the GORE EXCLUDER Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms. NLM Identifier: NCT02489539. Published July 3, 2015. Updated August 13, 2025. Accessed September 12, 2025. <https://clinicaltrials.gov/ct2/show/NCT02489539>
2. Data on file.



Consult Instructions
for Use

eifu.goremedical.com

Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx Only

INDICATIONS FOR USE: The GORE® EXCLUDER® Conformable AAA Endoprosthesis is intended to exclude the aneurysm from the blood circulation in patients diagnosed with infrarenal abdominal aortic aneurysm (AAA) disease and who have appropriate anatomy as described below: Adequate iliac/femoral access; Infrarenal aortic neck treatment diameter range of 16–32 mm and a minimum aortic neck length of 10 mm; Proximal aortic neck angulation $\leq 90^\circ$; Iliac artery treatment diameter range of 8–25 mm and iliac distal vessel seal zone length of at least 10 mm. The Aortic Extender Endoprosthesis and Iliac Extender Endoprosthesis Components are intended to be used after deployment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis. These extensions are intended to be used when additional length and/or sealing for aneurysmal exclusion is desired. **CONTRAINDICATIONS:** The GORE® EXCLUDER® Conformable AAA Endoprosthesis is contraindicated in: Patients with known sensitivities or allergies to the device materials. All components of the GORE® EXCLUDER® Conformable Endoprosthesis contain expanded polytetrafluoroethylene (ePTFE), fluorinated ethylene propylene (FEP), nitinol (nickel-titanium alloy) and gold. Patients with systemic infection who may be at increased risk of endovascular graft infection.

Products listed may not be available in all markets.

© 2025 W. L. Gore & Associates, Inc. All rights reserved. All trademarks referenced are trademarks of either a member of the Gore group of affiliated companies or their respective owners. “Together, improving life” mark and design are trademarks of a Gore company. 25AR1201-EN01 NOVEMBER 2025

W. L. Gore & Associates, Inc.
goremedical.com

Asia Pacific +65 67332882 Australia/New Zealand 1800 680 424 Europe 00800 6334 4673
United States Flagstaff, AZ 86004 800 437 8181 928 779 2771

